Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAnhui Provincial Cancer Hospital
About this trial
To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer
Eligibility criteria
Qualifiers
Age≥18 years old, male or female, signed Informed Consent Form (ICF);
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
Histologically or cytologically confirmed ES-SCLC;
No prior systemic treatment for ES-SCLC;
Disqualifiers
Active leptomeningeal disease or uncontrolled, untreated brain metastasis;
Prior therapy with an antibody or drug against immune checkpoint pathways, including but not limited to, anti program death receptor-1 (anti-PD-1), anti-PD-L1, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA-4) antibody;
Was administered a live vaccine ≤ 4 weeks before treatment;
Active autoimmune diseases or history of autoimmune diseases that may relapse;
Trial design
Treatments tested in this trial
- Tislelizumab, Carboplatin /Cisplatin, Etoposide
Treatment groups
56 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov